ENTITY
Celltrion

Celltrion (068270 KP)

25
Analysis
Health Care • South Korea
Celltrion, Inc. produces and sells biosimilar products, as well as consignment processing services for other businesses.
more
•14 May 2016 07:55

What's All the Fuss About Quantitative Easing in Korea?

There have been lots of discussions in Korea's media about Korea's version of Quantitative Easing in the past several weeks, especially after...

Logo
287 Views
Share
•29 Apr 2016 17:21

Korea Stock Market Monthly Recap #1 - (April 2016)

This is the first Korea Stock Market Monthly Recap, which we will attempt to publish on a monthly basis. The purpose our monthly recap are as...

Logo
308 Views
Share
•22 Apr 2016 10:10

How Korea National Pension Fund Is Exerting Pressure on Companies to Raise Dividends

Korea National Pension Fund (KNPF), the third largest pension fund in the world, has been exerting more pressure on Korean companies to raise their...

Logo
332 Views
Share
bearish•Celltrion Inc
•09 Apr 2016 05:22

U.S. Remsima Expectations Too Optimistic

USFDA approved Celltrion’s Remsima, a biosimilar for JNJ’s Remicade, for use in treating rheumatoid arthritis, ulcerative colitis, Crohn’s, and...

Share
bearish•Celltrion Inc
•26 Mar 2016 21:33

Serious Questions to Consider

Our initial post on Celltrion focused on the fundamental risk of whether the company could meet the market's high expectations for its first...

Share
x